Jülich, 20 March 2018 – In what represents a first milestone on the road to application, the drug candidate for the treatment of Alzheimer’s disease, PRI-002, has received approval for phase I clinical trials. At an independent clinic, the potential Alzheimer’s drug will initially be assessed under strict requirements to see whether it is safe for humans. The drug was developed at Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. In September 2017, Priavoid GmbH was founded as a spin-off of Forschungszentrum Jülich with the aim of launching the drug on market.